# ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.

> **NCT07390409** · — · NOT_YET_RECRUITING · sponsor: **Desmond Tutu HIV Foundation** · enrollment: 3700 (estimated)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Lenacapavir Injection
- **DRUG:** Cabotegravir (CAB) LA
- **DRUG:** Tenofovi-Emtricitabine (TDF/FTC) tablet

## Key facts

- **NCT ID:** NCT07390409
- **Lead sponsor:** Desmond Tutu HIV Foundation
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2028-03
- **Final completion:** 2028-05
- **Target enrollment:** 3700 (ESTIMATED)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07390409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07390409, "ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07390409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*